Research programme: hormone therapies - Juniper Pharmaceuticals

Drug Profile

Research programme: hormone therapies - Juniper Pharmaceuticals

Alternative Names: Estrogen/progesterone intravaginal - Juniper Pharmaceuticals; JNP 0201; JNP 0301; Progesterone intravaginal - Juniper Pharmaceuticals

Latest Information Update: 01 Feb 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Juniper Pharmaceuticals
  • Class Gonadal steroid hormones; Hormonal replacements
  • Mechanism of Action Estrogen receptor modulators; Progesterone receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Menopausal syndrome; Preterm labour

Most Recent Events

  • 26 Jan 2017 Juniper Pharmaceuticals announces its intention to file IND application with the US FDA for JNP 0301 in the first half of 2018
  • 06 Jan 2017 Juniper Pharmaceuticals expects to submit an IND application for JNP 0201 to the US FDA in 2018
  • 06 Jan 2017 Juniper Pharmaceuticals intends to initiate IND-enabling studies for JNP 0201 in 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top